Aptose commences dosing first CLL patient in phase 1 study of CG-806
Category: #health  By Pankaj Singh  Date: 2019-07-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Aptose commences dosing first CLL patient in phase 1 study of CG-806

Initial data from the first two cohorts has demonstrated MYC inhibition in patients with acute myelodysplastic syndrome (MDS) and myeloid leukemia (AML).

The clinical-stage company Aptose Biosciences Inc. has reportedly announced that it has started phase 1a/b dose-escalation trial by dosing CG-806 to the patients with small lymphocytic lymphoma (SLL), non-Hodgkin lymphomas (NHL) or chronic lymphocytic leukemia (CLL). CG-806 is the company’s highly potent, first-in-class pan-FLT3/pan-BTK inhibitor.

Apparently, the patients with small lymphocytic lymphoma (SLL), non-Hodgkin lymphomas (NHL) or chronic lymphocytic leukemia (CLL) who have failed or are intolerant to standard therapies have been dosed in the trial. Simultaneously, the company has successfully concluded the first two dose levels of the Phase 1b clinical study of MYC inhibitor APTO-253 and commenced dosing the third dose unit. Initial data from the first two cohorts has demonstrated MYC inhibition in patients with acute myelodysplastic syndrome (MDS) and myeloid leukemia (AML).

William G. Rice, Ph.D., Chief Executive Officer, Chairman and President, Aptose, reportedly expressed pleasure that the much anticipated first-in-human dosing with CG-806 has occurred and it has successfully started CG-806 oral dosing in a patient enduring CLL. CG-806 is a highly effective non-covalent inhibitor of all forms of FLT3 and BTK driver kinases which concurrently dominates multiple oncogenic signaling pathways on which cancer cells depend for survival, yet with a precision which evades targets typically linked with toxicity, he further added.

Dr. Rice further noted that the organization has completed dosing of the first two cohorts in a Phase 1b trial with its APTO-253 MYC inhibitor, with just one patient needed in each cohort. Both subjects completed the 28-day cycle and felt reductions of MYC gene expression in their peripheral blood cells, a vital finding as MYC performs a central role in the oncogenic process and the third dose unit at 66mg/m2 has been enrolling effectively for a total of three planned subjects, he added.

Source credit: https://ir.aptose.com/news-releases/news-release-details/aptose-doses-first-cll-patient-phase-1-study-cg-806-and-doses



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Emergency Care Partners finalizes its merger with Chicago’s IEMS
Emergency Care Partners finalizes its merger with Chicago’s IEMS
By Pankaj Singh

With rising cases of roadside accidents worldwide, the need for emergency medical facilities have increased considerably in recent years. These facilities offer immediate assistance without any appointments, which make...

Zelegent expands to OSA therapeutics with MISH platform acquisition
Zelegent expands to OSA therapeutics with MISH platform acquisition
By Pankaj Singh

  • MISH Technology stands for Minimally Invasive Suspension of the Hyoid and is a novel pre-clinical product line meant to treat obstructive sleep apnea (OSA).
  • SunGen Pharma and Elite Pharmaceuticals file an ANDA with the FDA
    SunGen Pharma and Elite Pharmaceuticals file an ANDA with the FDA
    By Pankaj Singh

    This is the second ANDA filed by both the companies, giving Elite Pharmaceutical the exclusive right to retail the drug.

    Elite Pharmaceuticals, Inc. a pharmaceutica...